Advertisement
Screener

Tenaya Therapeutics, Inc. (TNYA) Increase Decrease In Operating Lease Liability

2.8 / 5 stars · 68/120 Roast Me

Tenaya Therapeutics, Inc. Increase Decrease In Operating Lease Liability

Tenaya Therapeutics, Inc. (TNYA) reported Increase Decrease In Operating Lease Liability of -$1.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-05

  • Tenaya Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$740.00K.
  • Tenaya Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$713.00K.
  • Tenaya Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$697.00K.
  • Tenaya Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$683.00K.
  • Tenaya Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2025 was -$2.78M.
  • Tenaya Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2024 was -$4.12M.
  • Tenaya Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2023 was -$4.12M.
  • Tenaya Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2022 was -$3.11M.
Period endIncrease Decrease In Operating Lease Liability 3 monthIncrease Decrease In Operating Lease Liability 6 monthIncrease Decrease In Operating Lease Liability 9 monthIncrease Decrease In Operating Lease Liability 12 month
2026-06-30-$740.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
-$1.45M
10-Q · filed 2026-08-05
-$2.15M
derived: sum of 3 quarters · filed 2026-08-05
-$2.83M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31-$713.00K
10-Q · filed 2026-05-06
-$1.41M
derived: sum of 2 quarters · filed 2026-05-06
-$2.09M
derived: sum of 3 quarters · filed 2026-05-06
-$2.79M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31-$697.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11
-$1.38M
derived: sum of 2 quarters · filed 2026-03-11
-$2.08M
derived: sum of 3 quarters · filed 2026-08-05
-$2.78M
10-K · filed 2026-03-11
2025-09-30-$683.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
-$1.38M
derived: sum of 2 quarters · filed 2026-08-05
-$2.08M
10-Q · filed 2025-11-10
-$3.01M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30-$701.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
-$1.40M
10-Q · filed 2026-08-05
-$2.33M
derived: sum of 3 quarters · filed 2026-08-05
-$3.36M
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31-$697.00K
10-Q · filed 2026-05-06
-$1.63M
derived: sum of 2 quarters · filed 2026-05-06
-$2.66M
derived: sum of 3 quarters · filed 2026-05-06
-$3.76M
derived: sum of 4 quarters · filed 2026-05-06
2024-12-31-$930.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11
-$1.97M
derived: sum of 2 quarters · filed 2026-03-11
-$3.06M
derived: sum of 3 quarters · filed 2026-03-11
-$4.12M
10-K · filed 2026-03-11
2024-09-30-$1.03M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
-$2.13M
derived: sum of 2 quarters · filed 2025-11-10
-$3.19M
10-Q · filed 2025-11-10
-$4.26M
derived: sum of 4 quarters · filed 2025-11-10
2024-06-30-$1.09M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06
-$2.15M
10-Q · filed 2025-08-06
-$3.22M
derived: sum of 3 quarters · filed 2025-08-06
-$4.28M
derived: sum of 4 quarters · filed 2025-08-06
2024-03-31-$1.06M
10-Q · filed 2025-05-07
-$2.13M
derived: sum of 2 quarters · filed 2025-05-07
-$3.19M
derived: sum of 3 quarters · filed 2025-05-07
-$4.20M
derived: sum of 4 quarters · filed 2025-05-07
2023-12-31-$1.07M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10
-$2.13M
derived: sum of 2 quarters · filed 2025-03-10
-$3.14M
derived: sum of 3 quarters · filed 2025-03-10
-$4.12M
10-K · filed 2025-03-10
2023-09-30-$1.06M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06
-$2.08M
derived: sum of 2 quarters · filed 2024-11-06
-$3.06M
10-Q · filed 2024-11-06
-$4.01M
derived: sum of 4 quarters · filed 2024-11-06
2023-06-30-$1.02M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
-$2.00M
10-Q · filed 2024-08-08
-$2.96M
derived: sum of 3 quarters · filed 2024-08-08
-$3.90M
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31-$979.00K
10-Q · filed 2024-05-14
-$1.94M
derived: sum of 2 quarters · filed 2024-05-14
-$2.88M
derived: sum of 3 quarters · filed 2024-05-14
-$3.55M
derived: sum of 4 quarters · filed 2024-05-14
2022-12-31-$960.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18
-$1.90M
derived: sum of 2 quarters · filed 2024-03-18
-$2.57M
derived: sum of 3 quarters · filed 2024-03-18
-$3.11M
10-K · filed 2024-03-18
2022-09-30-$941.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08
-$1.61M
derived: sum of 2 quarters · filed 2023-11-08
-$2.15M
10-Q · filed 2023-11-08
-$2.67M
derived: sum of 4 quarters · filed 2023-11-08
2022-06-30-$673.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09
-$1.21M
10-Q · filed 2023-08-09
-$1.73M
derived: sum of 3 quarters · filed 2023-08-09
-$1.93M
derived: sum of 4 quarters · filed 2023-08-09
2022-03-31-$533.00K
10-Q · filed 2023-05-10
-$1.05M
derived: sum of 2 quarters · filed 2023-05-10
-$1.26M
derived: sum of 3 quarters · filed 2023-05-10
-$1.62M
derived: sum of 4 quarters · filed 2023-05-10
2021-12-31-$520.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08
-$727.00K
derived: sum of 2 quarters · filed 2023-03-08
-$1.09M
derived: sum of 3 quarters · filed 2023-03-08
-$1.47M
10-K · filed 2023-03-08
2021-09-30-$207.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10
-$568.00K
derived: sum of 2 quarters · filed 2022-11-10
-$952.00K
10-Q · filed 2022-11-10
2021-06-30-$361.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10
-$745.00K
10-Q · filed 2022-08-10
2021-03-31-$384.00K
10-Q · filed 2022-05-11

Similar stocks

Stock NameCountryMarket CapPE Ratio
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48
enGene Therapeutics Inc. (ENGN)$0.129B-0.92
Humacyte, Inc. (HUMA)United States$0.155B-2.26
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83
LENZ Therapeutics, Inc. (LENZ)United States$0.117B-1.41
Black Diamond Therapeutics, Inc. (BDTX)United States$0.109B-2.48
Voyager Therapeutics, Inc. (VYGR)United States$0.173B-1.99